Upstream Bio Inc. (UPB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Upstream Bio Inc. (UPB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.99

0.78 (6.96%)

At close: Jan 15, 2025, 3:59 PM

12.00

0.08%

After-hours Jan 15, 2025, 04:00 PM EST

undefined% (undefined)

Bid	11.8
Market Cap	642.62M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.36
PE Ratio (ttm)	-8.82
Forward PE	n/a
Analyst	Buy

Ask	18
Volume	138,448
Avg. Volume (20D)	341,363
Open	11.44
Previous Close	11.21
Day's Range	11.13 - 12.01
52-Week Range	10.36 - 29.46
Beta	undefined

About UPB

A detailed description of the company is not yet available....

[Show more]

Industry n/a

Sector n/a

IPO Date n/a

Employees 38

Stock Exchange NASDAQ

Ticker Symbol UPB

Analyst Forecast

According to 4 analyst ratings, the average rating for UPB stock is "Buy." The 12-month stock price forecast is $56.5, which is an increase of 371.23% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+8.91%

Upstream shares are trading higher after multiple ... Unlock content with Pro Subscription

News

4 weeks ago · seekingalpha.com

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Rele...

2 months ago · marketbeat.com

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical...

2 months ago · benzinga.com

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.